SCHEMBL4886115

SCHEMBL4886115

COC(=O)c1cccc(-n2c(=O)n([C@H]3CC[C@@H](NC(=O)C4CC4)CC3)c(=O)c3cc(F)cnc32)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.39
PDE4D Q08499 3/20 0.39
TNF P01375 3/20 0.39
LITAF Q99732 3/20 0.39
PDE4A P27815 1/20 0.39
PDE4C Q08493 1/20 0.39
TTK P33981 5/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
MAPK14 Q16539 1/20 0.38
POLB P06746 1/20 0.37
LMNA P02545 1/20 0.37
EPHX2 P34913 2/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886119 1.00 PDE4B (0.39) PDE4BPDE4DTNFLITAFPDE4A
SCHEMBL4879121 0.97 TTK (0.39) PDE4BPDE4DTNFLITAFPDE4A
SCHEMBL4879107 0.97 TTK (0.39) PDE4BPDE4DTNFLITAFPDE4A
SCHEMBL4875790 0.96 TTK (0.40) PDE4BPDE4DTNFLITAFPDE4A
SCHEMBL4875799 0.96 TTK (0.40) PDE4BPDE4DTNFLITAFPDE4A
SCHEMBL4883220 0.95 TTK (0.40) PDE4BPDE4DTNFLITAFPDE4A
SCHEMBL4883226 0.95 TTK (0.40) PDE4BPDE4DTNFLITAFPDE4A
SCHEMBL4870413 0.92 PDE4B (0.40) PDE4BPDE4DTNFLITAFPDE4A
SCHEMBL4870421 0.92 PDE4B (0.40) PDE4BPDE4DTNFLITAFPDE4A
SCHEMBL4879164 0.90 PDE4B (0.38) PDE4BPDE4DTNFLITAFPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases ASTRAZENECA AB (SE) 2008-09-18 US claimed
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases ASTRAZENECA AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases PDE4A, PDE4B, PDE5A PDE4B 2/4885PDE4D 7/4885TNF 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.